We serve Chemical Name:4-(3,5-dimethylpyrazol-1-yl)butanoic acid CAS:890593-72-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(3,5-dimethylpyrazol-1-yl)butanoic acid
CAS.NO:890593-72-3
Synonyms:4-(3,5-dimethylpyrazol-1-yl)butanoic acid
Molecular Formula:C9H14N2O2
Molecular Weight:182.22000
HS Code:2933199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:55.12000
Exact Mass:182.10600
LogP:1.36470
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-(3,5-dimethylpyrazol-1-yl)butanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(3,5-dimethylpyrazol-1-yl)butanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(3,5-dimethylpyrazol-1-yl)butanoic acid Use and application,4-(3,5-dimethylpyrazol-1-yl)butanoic acid technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 4-Pyrimidinamine, 6-methyl- (9CI) manufacturers About eight months after originally teaming up on neuromuscular diseases, Takeda and PeptiDream have expanded the pact to include several central nervous system targets, while revealing the tie-up could be worth more than $3.5 billion. Dyclonine suppliers Jan Vertommen, Senior Director, Commercial Development, Lonza, said, “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. Benzylboronic acid pinacol ester vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 4-Pyrimidinamine, 6-methyl- (9CI) manufacturers About eight months after originally teaming up on neuromuscular diseases, Takeda and PeptiDream have expanded the pact to include several central nervous system targets, while revealing the tie-up could be worth more than $3.5 billion. Dyclonine suppliers Jan Vertommen, Senior Director, Commercial Development, Lonza, said, “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. Benzylboronic acid pinacol ester vendor & factory.
